Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Abscess
Staphylococcus aureus Small Colony Variants (SCVs): a road map for the metabolic pathways involved in persistent infections.
Acquired Immunodeficiency Syndrome
Arginine deiminase gene of an AIDS-associated mycoplasma, Mycoplasma incognitus.
Adenocarcinoma
Arginine deiminase originating from Lactococcus lactis ssp. lactis American Type Culture Collection (ATCC) 7962 induces G1-phase cell-cycle arrest and apoptosis in SNU-1 stomach adenocarcinoma cells.
Arthritis
[Protein arginine deiminase of oral microbiome plays a causal role in the polyarthritis rheumatoid initiating].
Arthritis, Rheumatoid
Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans.
Arthritis, Rheumatoid
Lack of Association among Peptidyl Arginine Deiminase Type 4 Autoantibodies, PADI4 Polymorphisms, and Clinical Characteristics in Rheumatoid Arthritis.
Arthritis, Rheumatoid
Response to 'Peptidyl arginine deiminase type IV (PADI4) haplotypes interact with shared epitope regardless of anti-cyclic citrullinated peptide antibody or erosive joint status in rheumatoid arthritis: a case control study'.
Arthritis, Rheumatoid
[Peptidyl arginine deiminase 4 participates in the pathogenesis of rheumatoid arthritis by influencing histone methylation].
Breast Neoplasms
Arginine Deiminase Induces Immunogenic Cell Death and Is Enhanced by N-acetylcysteine in Murine MC38 Colorectal Cancer Cells and MDA-MB-231 Human Breast Cancer Cells In Vitro.
Breast Neoplasms
Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells.
Carcinogenesis
ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance.
Carcinoma
Development and characterization of macrophage hybridomas derived from murine peritoneal exudate cells.
Carcinoma
Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas.
Carcinoma
Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase.
Carcinoma, Hepatocellular
A potential antitumor drug (arginine deiminase) reengineered for efficient operation under physiological conditions.
Carcinoma, Hepatocellular
A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients.
Carcinoma, Hepatocellular
An Engineered Arginase FC Protein Inhibits Tumor Growth In Vitro and In Vivo.
Carcinoma, Hepatocellular
Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-?B signaling.
Carcinoma, Hepatocellular
Arginine deiminase expressed in vivo, driven by human telomerase reverse transcriptase promoter, displays high hepatoma targeting and oncolytic efficiency.
Carcinoma, Hepatocellular
Arginine deiminase, a potential anti-tumor drug.
Carcinoma, Hepatocellular
Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study.
Carcinoma, Hepatocellular
Blocking autophagy enhanced leukemia cell death induced by recombinant human arginase.
Carcinoma, Hepatocellular
Decreasing the immunogenicity of arginine deiminase enzyme via structure-based computational analysis.
Carcinoma, Hepatocellular
Directed Evolution of an Antitumor Drug (Arginine Deiminase PpADI) for Increased Activity at Physiological pH.
Carcinoma, Hepatocellular
Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.
Carcinoma, Hepatocellular
Drug evaluation: ADI-PEG-20--a PEGylated arginine deiminase for arginine-auxotrophic cancers.
Carcinoma, Hepatocellular
Expression of arginine deiminase from Pseudomonas plecoglossicida CGMCC2039 in Escherichia coli and its anti-tumor activity.
Carcinoma, Hepatocellular
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation.
Carcinoma, Hepatocellular
Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.
Carcinoma, Hepatocellular
Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.
Carcinoma, Hepatocellular
Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
Carcinoma, Hepatocellular
Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis.
Carcinoma, Hepatocellular
Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies.
Carcinoma, Hepatocellular
Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma.
Carcinoma, Hepatocellular
Protein engineering of the antitumor enzyme PpADI for improved thermal resistance.
Carcinoma, Hepatocellular
Rapid evolution of arginine deiminase for improved anti-tumor activity.
Carcinoma, Hepatocellular
Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma.
Carcinoma, Hepatocellular
Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase.
Carcinoma, Renal Cell
Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase.
Cerebellar Ataxia
Cognitive impairment in ARCA-1, a newly discovered pure cerebellar ataxia syndrome.
Cerebellar Diseases
Clinical and genetic study of autosomal recessive cerebellar ataxia type 1.
Colitis
Pegylated arginine deiminase downregulates colitis in murine models.
Colorectal Neoplasms
Arginine Deiminase Induces Immunogenic Cell Death and Is Enhanced by N-acetylcysteine in Murine MC38 Colorectal Cancer Cells and MDA-MB-231 Human Breast Cancer Cells In Vitro.
Dental Caries
A Highly Arginolytic Streptococcus Species That Potently Antagonizes Streptococcus mutans.
Dental Caries
Caries-free subjects have high levels of urease and arginine deiminase activity.
Dental Caries
Cleansing effect of acidic L-arginine on human oral biofilm.
Dental Caries
Could alkali production be considered an approach for caries control?
Dental Caries
Diversity in Antagonistic Interactions between Commensal Oral Streptococci and Streptococcus mutans.
Dental Caries
Effect of arginine on the growth and biofilm formation of oral bacteria.
Dental Caries
Effects of Arginine on Growth, Virulence Gene Expression, and Stress Tolerance by Streptococcus mutans.
Dental Caries
In Vivo Colonization with Candidate Oral Probiotics Attenuates Colonization and Virulence of Streptococcus mutans.
Dental Caries
Oral Microbiome Metabolism: From "Who Are They?" to "What Are They Doing?".
Dental Caries
The effect of arginine on oral biofilm communities.
Dental Plaque
Correlations of oral bacterial arginine and urea catabolism with caries experience.
Dental Plaque
Effects of Arginine on Growth, Virulence Gene Expression, and Stress Tolerance by Streptococcus mutans.
Dental Plaque
Fluoride, triclosan and organic weak acids as modulators of the arginine deiminase system in biofilms and suspension cells of oral streptococci.
Dental Plaque
In Vivo Colonization with Candidate Oral Probiotics Attenuates Colonization and Virulence of Streptococcus mutans.
Diphtheria
Anticancer Activity of Bacterial Proteins and Peptides.
Dysarthria
Clinical and genetic study of autosomal recessive cerebellar ataxia type 1.
Epstein-Barr Virus Infections
Arginine Methyltransferases Are Regulated by Epstein-Barr Virus in B Cells and Are Differentially Expressed in Hodgkin's Lymphoma.
Giardiasis
Multilevel Approach for the Treatment of Giardiasis by Targeting Arginine Deiminase.
Giardiasis
Polymeric immunoglobulin receptor in intestinal immune defense against the lumen-dwelling protozoan parasite Giardia.
Glioblastoma
Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo.
Glioma
A Phase I study of pegylated arginine deiminase (pegargiminase), cisplatin and pemetrexed in argininosuccinate synthetase 1-deficient recurrent high-grade glioma.
Hepatitis C
Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis.
Hepatitis C, Chronic
Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis.
Hypersensitivity
?ccurrence of bacterial spot caused by Xanthomonas arboricola pv. pruni on peach and apricot in Serbia.
Hypersensitivity
A New Disease, Bacterial Leaf Spot of Rape, Caused by Atypical Pseudomonas viridiflava in South Korea
Hypersensitivity
A New Disease, Bacterial Leaf Spot of Rape, Caused by Atypical Pseudomonas viridiflava in South Korea.
Hypersensitivity
Brown Blotch Caused by Pseudomonas tolaasii on Cultivated Pleurotus eryngii in Spain.
Hypersensitivity
First Report of Bacterial Blight of Sugar Beet Caused by Pseudomonas syringae pv. aptata in Georgia, USA.
Hypersensitivity
First Report of Bacterial Canker Caused by Pseudomonas syringae pv. morsprunorum Race 1 on Cherry in Chile.
Hypersensitivity
First Report of Bacterial Canker of Kiwifruit Caused by Pseudomonas syringae pv. actinidiae in Turkey.
Hypersensitivity
First Report of Bacterial Leaf Spot Caused by Pseudomonas syringae pv. aptata on Swiss Chard, Beta vulgaris subsp. vulgaris, in Arizona.
Hypersensitivity
First report of bacterial leaf spot disease on sunflower (Helianthus annuus) caused by Pseudomonas viridiflava in South Korea.
Hypersensitivity
First Report of Bacterial Leaf Spot of Coriander Caused by Pseudomonas syringae pv. coriandricola in India.
Hypersensitivity
First Report of Bacterial Leaf Spot of Witloof, Caused by Pseudomonas cichorii in Korea.
Hypersensitivity
First Report of Bacterial Leaf Spot on Cichorium intybus Caused by Pseudomonas cichorii in Florida.
Hypersensitivity
First Report of Copper-Tolerant Pseudomonas syringae pv. tomato in Virginia.
Hypersensitivity
First Report of Leaf Spot Caused by Pseudomonas cichorii on Coreopsis lanceolata in Italy.
Hypersensitivity
First Report of Pseudomonas syringae pv. syringae Causing Bacterial Leaf Spots of Oil Pumpkin (Cucurbita pepo) in Serbia.
Hypersensitivity
First Report of Pseudomonas syringae pv. tomato Race 1 on Tomato in California.
Hypersensitivity
First report of Pseudomonas syringae pv. tomato race 1 on tomato in California.
Hypersensitivity
Pseudomonas viridiflava: An internal outsider of the Pseudomonas syringae species complex.
Hypotension
Enzymic degradation of plasma arginine using arginine deiminase inhibits nitric oxide production and protects mice from the lethal effects of tumour necrosis factor alpha and endotoxin.
Infections
Anaerobic arginine metabolism of Mycobacterium tuberculosis is mediated by arginine deiminase (arcA), but is not essential for chronic persistence in an aerogenic mouse model of infection.
Infections
High-resolution transcriptomic analysis of the adaptive response of staphylococcus aureus during acute and chronic phases of osteomyelitis.
Infections
Identification and characterization of the arginine deiminase system of Streptococcus canis.
Infections
Role of arginine deiminase in thymic atrophy during experimental Streptococcus pyogenes infection.
Infections
The Arginine Deiminase Pathway Impacts Antibiotic Tolerance during Biofilm-Mediated Streptococcus pyogenes Infections.
Leukemia
A potential antitumor drug (arginine deiminase) reengineered for efficient operation under physiological conditions.
Leukemia
Apoptotic cell death of human T lymphoblastoid cells induced by arginine deiminase.
Leukemia
Apoptotic effects of selected strains of lactic acid bacteria on a human T leukemia cell line are associated with bacterial arginine deiminase and/or sphingomyelinase activities.
Leukemia
Arginine deiminase enhances dexamethasone-induced cytotoxicity in human T-lymphoblastic leukemia CCRF-CEM cells.
Leukemia
Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis.
Leukemia, Myeloid, Acute
A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients.
Leukemia, Myeloid, Acute
Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo.
Liver Neoplasms
Regression of hepatocellular cancer in a patient treated with arginine deiminase.
Lung Neoplasms
Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase.
Lung Neoplasms
Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapy.
Lung Neoplasms
Phase II Study of Arginine Deprivation Therapy With Pegargiminase in Patients With Relapsed Sensitive or Refractory Small-cell Lung Cancer.
Lymphoma
L-arginine enhances arginine deiminase induced human lymphoma cell growth inhibition through NF-kBp65 and p53 expression in vitro.
Lymphoma
Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis.
Lymphoma, Large B-Cell, Diffuse
Abnormal behavior of gamma-committed B lymphocytes probed by a lymphocyte blastogenesis inhibitory factor in autoimmune MRL mice.
Lymphoma, Large B-Cell, Diffuse
Identification and purification of arginine deiminase that originated from Mycoplasma arginini.
Malaria
Gateways to clinical trials.
Melanoma
A lymphocyte blastogenesis inhibitory factor (LBIF) reversibly arrests a human melanoma cell line, A375, at G1 and G2 phases of cell cycle.
Melanoma
A potential antitumor drug (arginine deiminase) reengineered for efficient operation under physiological conditions.
Melanoma
Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells.
Melanoma
An Engineered Arginase FC Protein Inhibits Tumor Growth In Vitro and In Vivo.
Melanoma
Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-?B signaling.
Melanoma
Arginine Deiminase Resistance in Melanoma Cells Is Associated with Metabolic Reprogramming, Glucose Dependence and Glutamine Addiction.
Melanoma
Arginine deiminase, a potential anti-tumor drug.
Melanoma
Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors.
Melanoma
Decreasing the immunogenicity of arginine deiminase enzyme via structure-based computational analysis.
Melanoma
Deprivation of arginine by recombinant human arginase in prostate cancer cells.
Melanoma
Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas.
Melanoma
Directed arginine deiminase evolution for efficient inhibition of arginine-auxotrophic melanomas.
Melanoma
Directed Evolution of an Antitumor Drug (Arginine Deiminase PpADI) for Increased Activity at Physiological pH.
Melanoma
Drug evaluation: ADI-PEG-20--a PEGylated arginine deiminase for arginine-auxotrophic cancers.
Melanoma
Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma.
Melanoma
Evaluation of Arginine Deiminase Treatment in Melanoma Xenografts Using (18)F-FLT PET.
Melanoma
Expression of arginine deiminase from Pseudomonas plecoglossicida CGMCC2039 in Escherichia coli and its anti-tumor activity.
Melanoma
Growth inhibition of human melanoma cells by a recombinant arginine deiminase expressed in Escherichia coli.
Melanoma
High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro.
Melanoma
Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma.
Melanoma
Improved method for expression and isolation of the Mycoplasma hominis arginine deiminase from the recombinant strain of Escherichia coli.
Melanoma
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation.
Melanoma
Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.
Melanoma
Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.
Melanoma
Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma.
Melanoma
Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.
Melanoma
Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
Melanoma
Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies.
Melanoma
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.
Melanoma
Protein engineering of the antitumor enzyme PpADI for improved thermal resistance.
Melanoma
Rapid evolution of arginine deiminase for improved anti-tumor activity.
Melanoma
Recombinant Human Arginase Inhibits the In vitro and In vivo Proliferation of Human Melanoma by Inducing Cell Cycle Arrest and Apoptosis.
Melanoma
Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma.
Melanoma
Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase.
Melanoma
Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4.
Melanoma
The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma.
Melanoma
[Mechanism of arginine deiminase activity by site-directed mutagenesis].
Melioidosis
A case of thoracic empyema due to suppurative melioidosis.
Mesothelioma
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.
Mesothelioma
Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase.
Mesothelioma, Malignant
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.
Mycoplasma Infections
Detection of mycoplasma infection of mammalian cells.
Neoplasms
A Competitive Flow Cytometry Screening System for Directed Evolution of Therapeutic Enzyme.
Neoplasms
A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients.
Neoplasms
A potential antitumor drug (arginine deiminase) reengineered for efficient operation under physiological conditions.
Neoplasms
Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells.
Neoplasms
ADI, autophagy and apoptosis: metabolic stress as a therapeutic option for prostate cancer.
Neoplasms
Amino Acid Degrading Enzymes and Autophagy in Cancer Therapy.
Neoplasms
Amino Acid Uptake Measured by [18F]AFETP Increases in Response to Arginine Starvation in ASS1-Deficient Sarcomas.
Neoplasms
Anticancer Activity of Bacterial Proteins and Peptides.
Neoplasms
Arginine deiminase and other antiangiogenic agents inhibit unfavorable neuroblastoma growth: potentiation by irradiation.
Neoplasms
Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.
Neoplasms
Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-?B signaling.
Neoplasms
Arginine deiminase enhances MCF-7 cell radiosensitivity by inducing changes in the expression of cell cycle-related proteins.
Neoplasms
Arginine Deiminase Enzyme Evolving As A Potential Antitumor Agent.
Neoplasms
Arginine deiminase expressed in vivo, driven by human telomerase reverse transcriptase promoter, displays high hepatoma targeting and oncolytic efficiency.
Neoplasms
Arginine Deiminase Resistance in Melanoma Cells Is Associated with Metabolic Reprogramming, Glucose Dependence and Glutamine Addiction.
Neoplasms
Arginine deiminase, a potential anti-tumor drug.
Neoplasms
Arginine deiminase: a potential inhibitor of angiogenesis and tumour growth.
Neoplasms
Arginine Deiminase: Current Understanding and Applications.
Neoplasms
Arginine deiminase: recent advances in discovery, crystal structure, and protein engineering for improved properties as an anti-tumor drug.
Neoplasms
Arginine depletion by arginine deiminase does not affect whole protein metabolism or muscle fractional protein synthesis rate in mice.
Neoplasms
Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer.
Neoplasms
Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo.
Neoplasms
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.
Neoplasms
Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment.
Neoplasms
Arginine Metabolism in Bacterial Pathogenesis and Cancer Therapy.
Neoplasms
Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors.
Neoplasms
Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapy.
Neoplasms
Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase-Mediated Eukaryotic Initiation Factor 2? Activity and Is Targetable by Pegylated Arginine Deiminase.
Neoplasms
Argininosuccinate Synthetase-1 (ASS1) Loss in High-Grade Neuroendocrine Carcinomas of the Urinary Bladder: Implications for Targeted Therapy with ADI-PEG 20.
Neoplasms
Aspergillus nidulans thermostable arginine deiminase-Dextran conjugates with enhanced molecular stability, proteolytic resistance, pharmacokinetic properties and anticancer activity.
Neoplasms
Biomimetic microbioreactor-supramolecular nanovesicles improve enzyme therapy of hepatic cancer.
Neoplasms
Blocking autophagy enhanced leukemia cell death induced by recombinant human arginase.
Neoplasms
Chemical modification by polyethylene glycol of the anti-tumor enzyme arginine deiminase from Mycoplasma arginini.
Neoplasms
Chromatin remodeling system p300-HDAC2-Sin3A is involved in Arginine Starvation-Induced HIF-1? Degradation at the ASS1 promoter for ASS1 Derepression.
Neoplasms
Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1?, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation.
Neoplasms
Citrullination of pyruvate kinase M2 by PADI1 and PADI3 regulates glycolysis and cancer cell proliferation.
Neoplasms
Collaboration Between RSK-EphA2 and Gas6-Axl RTK Signaling in Arginine Starvation Response That Confers Resistance to EGFR Inhibitors.
Neoplasms
Comparative proteomic analysis reveals metabolic variability of probiotic Enterococcus durans during aerobic and anaerobic cultivation.
Neoplasms
Comparative transcriptional analysis reveals distinct expression patterns of channel catfish genes after the first infection and re-infection with Aeromonas hydrophila.
Neoplasms
Crystal structures of arginine deiminase with covalent reaction intermediates; implications for catalytic mechanism.
Neoplasms
Decreasing the immunogenicity of arginine deiminase enzyme via structure-based computational analysis.
Neoplasms
Deprivation of arginine by recombinant human arginase in prostate cancer cells.
Neoplasms
Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas.
Neoplasms
Directed arginine deiminase evolution for efficient inhibition of arginine-auxotrophic melanomas.
Neoplasms
Directed Evolution of an Antitumor Drug (Arginine Deiminase PpADI) for Increased Activity at Physiological pH.
Neoplasms
Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.
Neoplasms
Drug evaluation: ADI-PEG-20--a PEGylated arginine deiminase for arginine-auxotrophic cancers.
Neoplasms
Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma.
Neoplasms
Enzymic degradation of plasma arginine using arginine deiminase inhibits nitric oxide production and protects mice from the lethal effects of tumour necrosis factor alpha and endotoxin.
Neoplasms
Expression of arginine deiminase from Pseudomonas plecoglossicida CGMCC2039 in Escherichia coli and its anti-tumor activity.
Neoplasms
Extrinsic nitric oxide donor partially reverses arginine deiminase induced cell growth inhibition through NFkappaB and Bcl-X L.
Neoplasms
High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro.
Neoplasms
Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20).
Neoplasms
Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma.
Neoplasms
Improved method for expression and isolation of the Mycoplasma hominis arginine deiminase from the recombinant strain of Escherichia coli.
Neoplasms
In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma arginini.
Neoplasms
Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.
Neoplasms
Insights into the modulation of optimum pH by a single histidine residue in arginine deiminase from Pseudomonas aeruginosa.
Neoplasms
International multicentre observational study to evaluate the association between perioperative red blood cell transfusions and 1-year mortality after major cancer surgery (ARCA-1): study design, statistical analysis plan and study protocol.
Neoplasms
Intracellular delivery of recombinant arginine deiminase (rADI) by heparin-binding hemagglutinin adhesion peptide restores sensitivity in rADI-resistant cancer cells.
Neoplasms
Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM.
Neoplasms
Molecular basis and current strategies of therapeutic arginine depletion for cancer.
Neoplasms
Mono-PEGylation of a Thermostable Arginine-Depleting Enzyme for the Treatment of Lung Cancer.
Neoplasms
MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
Neoplasms
Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.
Neoplasms
Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma.
Neoplasms
Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.
Neoplasms
Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
Neoplasms
PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration.
Neoplasms
Pegylated arginine deiminase downregulates colitis in murine models.
Neoplasms
Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis.
Neoplasms
Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion.
Neoplasms
PEGylation and pharmacological characterization of a potential anti-tumor drug, an engineered arginine deiminase originated from Pseudomonas plecoglossicida.
Neoplasms
Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.
Neoplasms
Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers.
Neoplasms
Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia.
Neoplasms
Phase I trial of arginine deprivation therapy with ADI-PEG 20 plus docetaxel in patients with advanced malignant solid tumors.
Neoplasms
Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma.
Neoplasms
Potent growth inhibition of human tumor cells in culture by arginine deiminase purified from a culture medium of a Mycoplasma-infected cell line.
Neoplasms
Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis.
Neoplasms
Protein engineering of the antitumor enzyme PpADI for improved thermal resistance.
Neoplasms
Purification, immobilization, and biochemical characterization of l-arginine deiminase from thermophilic Aspergillus fumigatus KJ434941: Anticancer activity in vitro.
Neoplasms
Quantitative Analysis of Autophagy using Advanced 3D Fluorescence Microscopy.
Neoplasms
Rapid evolution of arginine deiminase for improved anti-tumor activity.
Neoplasms
Rational surface engineering of an arginine deiminase (an antitumor enzyme) for increased PEGylation efficiency.
Neoplasms
Recombinant Bacillus caldovelox Arginase Mutant (BCA-M) Induces Apoptosis, Autophagy, Cell Cycle Arrest and Growth Inhibition in Human Cervical Cancer Cells.
Neoplasms
Recombinant human arginase induced caspase-dependent apoptosis and autophagy in non-Hodgkin's lymphoma cells.
Neoplasms
Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest.
Neoplasms
Resistance to the anti-proliferative activity of recombinant arginine deiminase in cell culture correlates with the endogenous enzyme, argininosuccinate synthetase.
Neoplasms
RNA interference of argininosuccinate synthetase restores sensitivity to recombinant arginine deiminase (rADI) in resistant cancer cells.
Neoplasms
Selective extracellular arginine deprivation by a single injection of cellular non-uptake arginine deiminase nanocapsules for sustained tumor inhibition.
Neoplasms
Single amino acid arginine starvation efficiently sensitizes cancer cells to canavanine treatment and irradiation.
Neoplasms
Suppression of human immunodeficiency virus type 1 replication by arginine deiminase of Mycoplasma arginini.
Neoplasms
Targeting arginine metabolism pathway to treat arginine-dependent cancers.
Neoplasms
The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.
Neoplasms
The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines.
Neoplasms
The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials.
Neoplasms
TRAIL stabilization and cancer cell sensitization to its pro-apoptotic activity achieved through genetic fusion with arginine deiminase.
Neoplasms
Tumor growth inhibitory activity of a lymphocyte blastogenesis inhibitory factor.
Neoplasms
[Mechanism of arginine deiminase activity by site-directed mutagenesis].
Neuroblastoma
Arginine deiminase and other antiangiogenic agents inhibit unfavorable neuroblastoma growth: potentiation by irradiation.
Neuroblastoma
Depletion of arginine by recombinant arginine deiminase induces nNOS-activated neurotoxicity in neuroblastoma cells.
Ovarian Neoplasms
Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas.
Pancreatic Neoplasms
Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-?B signaling.
Pancreatic Neoplasms
Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors.
Pancreatic Neoplasms
Exploiting arginine auxotrophy with pegylated arginine deiminase (ADI-PEG20) to sensitize pancreatic cancer to radiotherapy via metabolic dysregulation.
Pancreatic Neoplasms
Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.
Pancreatic Neoplasms
Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer.
Prostatic Neoplasms
Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.
Prostatic Neoplasms
Arginine starvation-associated atypical cellular death involves mitochondrial dysfunction, nuclear DNA leakage, and chromatin autophagy.
Prostatic Neoplasms
Cytoprotective effect of arginine deiminase on taxol-induced apoptosis in DU145 human prostate cancer cells.
Prostatic Neoplasms
Deprivation of arginine by recombinant human arginase in prostate cancer cells.
Pulmonary Fibrosis
Therapeutic targeting of argininosuccinate synthase 1 (ASS1)-deficient pulmonary fibrosis.
Retinoblastoma
Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma.
Sarcoma
A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas.
Sarcoma
Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors.
Sarcoma
Autoantibodies to PAD4 and BRAF in rheumatoid arthritis.
Sarcoma
New autoantigens in rheumatoid arthritis (RA): screening 8268 protein arrays with sera from patients with RA.
Shock, Septic
Expression of enterotoxin-coding genes in methicillin-resistant Staphylococcus aureus strains isolated from Mexican haemodialysis patients.
Small Cell Lung Carcinoma
Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapy.
Starvation
A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas.
Starvation
Amino Acid Uptake Measured by [18F]AFETP Increases in Response to Arginine Starvation in ASS1-Deficient Sarcomas.
Starvation
Chromatin remodeling system p300-HDAC2-Sin3A is involved in Arginine Starvation-Induced HIF-1? Degradation at the ASS1 promoter for ASS1 Derepression.
Starvation
Decreasing the immunogenicity of arginine deiminase enzyme via structure-based computational analysis.
Starvation
Systems level profiling of arginine starvation reveals MYC and ERK adaptive metabolic reprogramming.
Starvation
Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.
Starvation
Transcriptome analysis of the progressive adaptation of Lactococcus lactis to carbon starvation.
Stomach Neoplasms
Arginine deiminase originating from Lactococcus lactis ssp. lactis American Type Culture Collection (ATCC) 7962 induces G1-phase cell-cycle arrest and apoptosis in SNU-1 stomach adenocarcinoma cells.
Streptococcal Infections
Identification and characterization of the arginine deiminase system of Streptococcus canis.
Tooth Demineralization
Arginine Metabolism in Supragingival Oral Biofilms as a Potential Predictor of Caries Risk.
Tuberculosis
Anaerobic arginine metabolism of Mycobacterium tuberculosis is mediated by arginine deiminase (arcA), but is not essential for chronic persistence in an aerogenic mouse model of infection.
Urinary Bladder Neoplasms
Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase-Mediated Eukaryotic Initiation Factor 2? Activity and Is Targetable by Pegylated Arginine Deiminase.
Vaginosis, Bacterial
Microecology, bacterial vaginosis and probiotics: perspectives for bacteriotherapy.
Virus Diseases
Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
3.5.3.6 arginine deiminase
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
